Skip to content

Xentra

Leeds-based provider of subscription managed cybersecurity, digital compliance and safeguarding services for UK organizations.

Visit Website ↗ + Add to Compare Claim This Company
42/100Emerging / Unranked

Overview

Xentra is a Leeds, England provider of subscription-based managed cybersecurity, digital compliance and safeguarding services, sold through its STAX software bundles and a centralised customer portal. Chief executive is Henry Doyle.

It reports over 90 clients across enterprise and education, including Leeds United Football Club, Leeds Bradford Airport and the Shaw Education Trust. In July 2026 it secured £2.7 million from Maven Capital Partners, the Maven VCTs and NPIF II, with the investor saying annual recurring revenue has quadrupled over two years.

Innovation Matrix Assessment

Innovation Velocity 3/10

Packaged managed-service bundles; no evidence of novel technology development.

Operational Value 6/10

Bundled security, compliance and safeguarding eases adoption for resource-constrained organizations.

Market Momentum 4/10

Over 90 named-type clients and a £2.7M institutional round, with ARR reported to have quadrupled in two years.

Category Disruption 2/10

A managed-service model rather than a category-changing approach.

Real-World Efficacy 5/10

Named customers such as an airport and a football club offer credible, though uncontextualised, evidence.

Enduring Relevance 5/10

Managed security for mid-sized UK organizations will remain needed.

Why CISOs Should Care

Offers smaller UK organizations managed security and compliance on a subscription basis.

What Makes It Different

Combines cybersecurity, digital compliance and safeguarding in one subscription portal.

The Matrix Verdict

42/100 — EMERGING / UNRANKED

Xentra lands in the Emerging/Unranked tier: a credible, growing managed service provider whose value is delivery rather than technical innovation.

Editorial Note: Claims vs. Verified Findings

Customer counts and ARR growth come from the investor and company announcements; no independent efficacy data found. Founding year not confirmed.

Sources